written by reader A Michael Murphy New World Investor Tease

By xiexgp@gmail.com, July 24, 2014

Lynn Pozmanter was worried. Although she and her husband, Murray, were of average height, their beloved daughter Lauren always was short. And she knew it. When she asked her mom and dad why she was so short, they would say: ”You’ll grow, you’ll grow.”
By the time she was 12 years old and only 4’ 5”, she had fallen off the bottom of the growth chart. Finally, her doctor referred her to an endocrinologist. He found that she had growth hormone deficiency – her body did not produce enough growth hormone to stimulate normal growth. Further tests determined she was not about to grow much taller without medical intervention.
The specialists put her on human growth hormone. She grew 7 inches in two years, until her bones fused in puberty. She may stay on low dose human growth hormone for a few more years, to gain a few extra inches.
Patricia Costa was worried too. Her daughter also was short. By the time Nicole fit on a tricycle, kids her age were on two-wheelers. Sometimes short children can’t reach a water fountain or the lavatory in school, and the other kids make fun of them. Nicole’s day camp went to an amusement park that had a height requirement to go on the rides. Everyone rode except Nicole.
Nicole was on human growth hormone from age 8 to 13. Today, she’s a happy 5’ 2” adult.
Both of these kids were heroes, because they had to get a growth hormone shot every day – Lauren for two years and counting, Nicole for five years. Every day. Like juvenile diabetes, the diagnosis was a sentence to being stuck with a needle every day.
Until now. One company invented and patented needle-free injectors that could handle human growth hormone, administering the precise amount needed to boost a child’s growth, without needing to painfully stick the child everyday.


This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments
July 24, 2014 10:49 am

Possibly Antares (ATRS), but not positive.

👍 1
July 27, 2014 10:56 pm

Here’s a note I found on…Business Wire, downloaded from Yahoo Finance dated 7/26/14 “Antares Pharma, Inc. July 22, 2014 7:00 AM”
“… EWING, N.J.–(BUSINESS WIRE)–Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX® epinephrine and several other products. In the U.S., Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company’s corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.”

It apparently closed at $2.05 (down $.05) on Friday 7/25/14.

I like the concept for their drug delivery system that gets around syringe injections for parents to use with their kids. It would be a huge step forward if it could be applied for insulin because of the potential market size, which unfortunately is increasing at a rapid pace. Lots of people are squeamish about using needles. Looks like the current news is about a delivery system for a drug that treats low testosterone in men (male hypogonadism). Looking very briefly at this stock it appears to have a good future based on the technological concepts and their partnering with TEVA which tends to lend credibility and validation to Antares. The real questions lie with the business aspects